Stochter
Profile Picture
Global Finance News 18 Nov 2026, 18:09
Regeneron Wins EU Approval for More Flexible Libtayo Dosing Across Multiple Cancers

Regeneron Pharmaceuticals (NASDAQ: REGN) said the European Commission approved a more flexible dosing schedule for Libtayo across all six of its approved skin, lung and cervical cancer indications in the European Union.

The new regimen allows patients to receive 700 mg of Libtayo every six weeks after an initial 12 weeks of treatment at 350 mg every three weeks. The approval also permits subsequent 350 mg infusions to be shortened from 30 minutes to as little as 15 minutes for patients who tolerate the initial infusion well.

The expanded flexibility applies across indications including cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer and recurrent or metastatic cervical cancer. Regeneron said the approval was supported by clinical safety and efficacy data together with pharmacokinetic and pharmacodynamic modeling.

Strategically, the change could improve treatment convenience and reduce the burden of frequent clinic visits, potentially strengthening Libtayo’s competitive position in European oncology markets. A similar dosing regimen is under FDA review in the U.S., with a decision expected in March 2027.

Comments

No comments yet.

Ana sayfa